Keyword: Sangamo BioSciences
Sangamo Biosciences has been working on its zinc finger nuclease gene-editing platform for many years, long before the emergence of rival method CRISPR, but early readouts from trials haven’t been encouraging.
This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.
After bagging a new R&D leader at the start of the year, Sangamo has hired a new chief medical officer for its gene editing and therapy work.
The update adds to the impression that the gene therapy is a threat to assets including BioMarin’s valrox and Spark Therapeutics’ SPK-8011.
Sangamo saw its stock on the up this morning after it posted updates to a series of its trials using a new form of gene editing and cell therapies.
The treatment failed to have the hoped-for effects on patients with the rare disease MPS II, causing investors to drive Sangamo’s stock down 30%.
The hire gives Sangamo an R&D chief with deep immuno-oncology experience as it works to advance its pipeline.
In his new role as chief scientific officer, Gary Lee will head up the expansion of Senti’s synthetic biology platform.
Winson Tang is accused of telling a friend about a 2014 agreement between Sangamo and Biogen before the news became public.
The €72 million takeover positions Sangamo to move a CAR-carrying regulatory T cell therapy into testing in solid organ transplant patients next year.